Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2017-01-18

Summary

This is a Phase 2, multicenter, randomized study of two different dose regimens of eribulin mesylate in combination with intermittent erlotinib in patients with previously treated, advanced non-small cell lung cancer.

• Phase: Phase 2

Details

• Lead Sponsor: Eisai Inc.
• Treatments: Erlotinib Hydrochloride